Zanamivir (Relenza)

A guanido-neuraminic acid that is used to inhibit NEURAMINIDASE.

Also Known As:

Relenza; 2,3-Didehydro-2,4-Dideoxy-4-Guanidino-N-Acetyl-D-Neuraminic Acid; 2,3-Didehydro-2,4-Dideoxy-4-Guanidinyl-N-Acetylneuraminic Acid; 4-Guanidino-2,4-Dideoxy-2,3-Didehydro-N-Acetylneuraminic Acid; 4-Guanidino-2-Deoxy-2,3-Didehydro-N-Acetylneuraminic Acid; 4-Guanidino-Neu5Ac2en; 5-Acetylamino-2,6-Anhydro-4-Guanidino-3,4,5-Trideoxy-D-Galacto-Non-Enoic Acid; GG 167; GG-167; GG167; 4 Guanidino 2 Deoxy 2,3 Didehydro N Acetylneuraminic Acid; 4 Guanidino Neu5Ac2en; Acid, 4-Guanidino-2-Deoxy-2,3-Didehydro-N-Acetylneuraminic; 5-acetylamino-4-guanidino-6-(1,2,3-trihydroxypropyl)-5,6-dihydro-4H-pyran-2-carboxylic acid

Networked: 732 relevant articles (112 outcomes, 122 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Hurt, Aeron C: 18 articles (11/2020 - 01/2003)
2.	McKimm-Breschkin, Jennifer L: 13 articles (10/2021 - 02/2002)
3.	Ikematsu, Hideyuki: 12 articles (08/2020 - 06/2007)
4.	Gubareva, Larisa V: 11 articles (10/2021 - 03/2008)
5.	Boivin, Guy: 11 articles (01/2021 - 06/2002)
6.	Kashiwagi, Seizaburo: 11 articles (08/2020 - 06/2007)
7.	Kawai, Naoki: 11 articles (08/2020 - 06/2007)
8.	Barr, Ian G: 10 articles (01/2022 - 01/2003)
9.	Hayden, Frederick G: 9 articles (10/2021 - 03/2002)
10.	Abed, Yacine: 9 articles (01/2021 - 01/2006)

Related Diseases

1.	Human Influenza (Influenza) 11/01/2005 - "The protective efficacy of zanamivir versus placebo for SLCI was marginal, for all laboratory confirmed illnesses, but significant against culture proven and febrile influenza, suggesting zanamivir can be effective for outbreak control and symptom reduction of unvaccinated institutionalized residents. " 12/01/2001 - "(3) Zanamivir has no proven efficacy in preventing the spread of influenza by a treated patient. " 01/01/1999 - "Zanamivir, a potent inhibitor of influenza A and B virus neuraminidases, is protective against experimental human influenza when given intranasally twice daily. " 08/01/2007 - "Previous studies conducted primarily in non-high-risk subjects have reported the efficacy of inhaled zanamivir in preventing influenza. " 11/01/2002 - "Clinical trials of zanamivir have reported a reduced incidence of influenza complications among high-risk patients. "
2.	Infections 01/01/2010 - "He did well with complete clearance of the infection from the BAL after 10 days of Zanamivir, although the nasopharyngeal swabs remained positive for ten more days. " 01/24/1996 - "For all dose groups combined, GG167 prophylaxis was 82% effective in preventing laboratory evidence of infection and 95% effective in preventing febrile illness (P < .01 vs placebo). " 07/01/1999 - "This study demonstrates that intravenously administered zanamivir is distributed to the respiratory mucosa and is protective against infection and illness following experimental human influenza A virus inoculation." 09/01/2010 - "Compassionate use of intravenous zanamivir for the treatment of seriously ill patients, including those with H275Y H1N1 infections, has also shown promising results. " 07/01/1999 - "Safety and efficacy of intravenous zanamivir in preventing experimental human influenza A virus infection."
3.	Influenza in Birds (Avian Flu) 10/01/2006 - "Sixteen novel 4-triazole-modified zanamivir (1) analogues were synthesized using the click reactions, and their inhibitory activities against avian influenza virus (AIV, H5N1) were determined. " 04/01/2001 - "Thus, zanamivir is efficacious in treating avian influenza viruses that can be transmitted to mammals." 08/01/2012 - "Further preliminary anti-avian influenza virus (AIV, H5N1) activities against infected MDCK cells were evaluated, and D5 exerts ∼58% protective against AIV infection, which was comparable to zanamivir (∼67%). " 01/01/2011 - "[Effect of Zanamivir substance on infection induced by highly pathogenic avian influenza A/H5N1 in cell cultures]." 01/01/2010 - "Zanamivir for the treatment of avian influenza infections in humans."
4.	Virus Diseases (Viral Diseases) 05/01/2000 - "This study evaluated the efficacy, safety and tolerability of a 5-day course of twice daily inhaled zanamivir, 10 mg, compared with placebo in the treatment of symptomatic influenza A and B viral infections among children 5 to 12 years of age. " 12/01/2019 - "Severe myocarditis due to influenza A(H1N1)pdm09 viral infection in a young woman successfully treated with intravenous zanamivir: A case report." 08/01/2007 - "The most commonly reported AEs (>or=3% of subjects in each treatment group) were consistent with upper respiratory viral infection (headache: 17% zanamivir, 18% placebo; cough: 14% and 15%, respectively; throat and tonsil discomfort/pain: 13% and 14%). " 04/07/2016 - "Significantly, we show in cell-based drug-combination studies using virus infection blockade assays, that suramin acts synergistically with the anti-influenza virus drug zanamivir. " 10/15/2015 - "Prolonged treatment of an immunocompromised child with oseltamivir and zanamivir for A(H1N1)pdm09 virus infection led to the emergence of viruses carrying H275Y and/or E119G in the neuraminidase (NA). "
5.	Pneumonia (Pneumonitis) 05/01/2018 - "We studied whether zanamivir reduces pulmonary inflammation through inhibition of NO production in mice. " 10/01/2014 - "There was no significant effect of zanamivir on either self reported or radiologically confirmed pneumonia. " 04/09/2014 - "Zanamivir did not reduce the risk of self reported investigator mediated pneumonia (risk difference 0.17%, -0.73% to 0.70%) or radiologically confirmed pneumonia (-0.06%, -6.56% to 2.11%) in adults. " 05/01/2010 - "Intravenous zanamivir for patients with pneumonitis due to pandemic (H1N1) 2009 influenza virus." 01/01/2010 - "Prone Positioning and Intravenous Zanamivir may Represent Effective Alternatives for Patients with Severe ARDS Virus A (H1N1) Related Pneumonia in Hospitals with no Access to ECMO."

Related Drugs and Biologics

1.	Oseltamivir (Tamiflu)
2.	Neuraminidase (Sialidase)
3.	Zanamivir (Relenza)
4.	Antiviral Agents (Antivirals)
5.	Amantadine (Aman)
6.	Rimantadine
7.	laninamivir
8.	peramivir
9.	N-Acetylneuraminic Acid (Sialic Acid)
10.	oseltamivir carboxylate

Related Therapies and Procedures

1.	Therapeutics
2.	Chemoprevention
3.	Intranasal Administration
4.	Home Nursing (Nursing, Home)
5.	Aftercare (After-Treatment)